KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Invested Capital (2018 - 2025)

Historic Return on Invested Capital for Halozyme Therapeutics (HALO) over the last 10 years, with Q3 2025 value amounting to 0.31%.

  • Halozyme Therapeutics' Return on Invested Capital rose 1000.0% to 0.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year increase of 1000.0%. This contributed to the annual value of 0.25% for FY2024, which is 900.0% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Return on Invested Capital is 0.31%, which was up 1000.0% from 0.29% recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Invested Capital ranged from a high of 0.46% in Q3 2021 and a low of 0.12% during Q1 2023
  • Moreover, its 5-year median value for Return on Invested Capital was 0.23% (2024), whereas its average is 0.26%.
  • In the last 5 years, Halozyme Therapeutics' Return on Invested Capital soared by 5500bps in 2021 and then tumbled by -3200bps in 2023.
  • Halozyme Therapeutics' Return on Invested Capital (Quarter) stood at 0.44% in 2021, then plummeted by -70bps to 0.13% in 2022, then grew by 24bps to 0.16% in 2023, then skyrocketed by 40bps to 0.23% in 2024, then surged by 33bps to 0.31% in 2025.
  • Its last three reported values are 0.31% in Q3 2025, 0.29% for Q2 2025, and 0.25% during Q1 2025.